Manufacture by re-processing defective goods confirmed, while Modvat credit remained available on proof of duty payment.

Re-processing of defective bulk drugs returned by customers constituted manufacture because drying, milling, blending, testing, repacking, relabelling, new lot numbering, expiry dating and chemical treatment rendered the goods marketable again, and Note 11 to Chapter 29 treats such treatment as manufacture. The demand was not time-barred because the D-3 declarations disclosed only testing, while the actual extent of re-processing was not fully revealed, supporting invocation of the extended period. Modvat credit on duty-paid bulk drugs was admissible if duty-paying documents were produced to the satisfaction of the adjudicating authority; penalty and interest were therefore set aside for fresh consideration.

---

---

Issues: (i) Whether re-processing of defective bulk drugs returned by customers amounted to manufacture under Note 11 to Chapter 29 read with section 2(f) of the Central Excise Act; (ii) Whether the demand was barred by limitation and the extended period was invocable; (iii) Whether Modvat credit of duty paid on the bulk drugs was admissible and the penalty and interest could be sustained.

Issue (i): Whether re-processing of defective bulk drugs returned by customers amounted to manufacture under Note 11 to Chapter 29 read with section 2(f) of the Central Excise Act.

Analysis: The returned goods were subjected to processes such as drying, milling, blending, testing, repacking, re-labelling, allotment of new lot numbers and expiry dates, and in some cases chemical treatment. The Court found that the goods were returned because they were defective and unmarketable to the consumer, and that the treatment given by the assessee rendered them marketable again. Note 11 to Chapter 29 specifically treats adoption of any other treatment to render the product marketable to the consumer as manufacture.

Conclusion: The process amounted to manufacture and the assessee's contention was rejected.

Issue (ii): Whether the demand was barred by limitation and the extended period was invocable.

Analysis: The D-3 declarations disclosed only testing of the returned goods, whereas the actual processes undertaken included extensive re-processing. The Court held that the nature of the processes was not fully disclosed and that the allegation of value addition also supported invocation of the extended period. Revenue neutrality did not assist the assessee on these facts.

Conclusion: The extended period of limitation was invocable and the demand was not time-barred.

Issue (iii): Whether Modvat credit of duty paid on the bulk drugs was admissible and the penalty and interest could be sustained.

Analysis: The Court accepted that credit of duty already paid on the bulk drugs could not be denied merely because the procedural requirements for availing Modvat credit had not been followed, provided the duty-paying documents were produced to the satisfaction of the adjudicating authority. In view of the remand on credit, the penalty and interest were set aside and left for reconsideration by the adjudicating authority.

Conclusion: Modvat credit was held admissible subject to production of duty-paying documents, and the penalty and interest were set aside for fresh decision.

Final Conclusion: The appeals succeeded only to the limited extent of permitting Modvat credit on proof of duty payment, while the findings on manufacture and limitation were upheld.

Ratio Decidendi: Re-processing of defective goods that renders them marketable again constitutes manufacture where the tariff note so provides, and Modvat credit on duty-paid inputs cannot be denied merely for non-observance of procedure if the substantive entitlement is otherwise established.

---